soul trial oral semaglutide (NEJM 2025): led to a 14% ↓ in major CV events vs placebo in T2DM with ASCVD or CKD — no ↑ in serious AEs. #Semaglutide #CardioDiabetes #updatesinmedicine New data from the SOUL
Pay in 4 interest-free payments of $5.99 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Sep 1 - Sep 6

01127-3/asset/cb71a1fc-b829-4644-a5d6-f1f235f450bf/main.assets/gr2_lrg.jpg)



























